BiotechTube
Eligo Bioscience

Eligo Bioscience

Paris, France· Est.
eligo.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Eligo Bioscience is a private, preclinical-stage biotech based in Paris, developing a first-in-class platform for precision microbiome engineering. Its core GEM (Gene Editing of the Microbiome) platform enables the in vivo delivery of therapeutic DNA payloads to target bacteria, allowing for sequence-specific killing (SSAM), gene editing (GEM), or functional addition (FAME). The company, founded by CRISPR pioneers, is backed by notable investors and is advancing a pipeline focused on diseases causally linked to specific bacterial genes, as recently validated by a landmark 2024 publication in Nature.

Infectious DiseasesInflammatory DiseasesOncologyMetabolic Diseases

Technology Platform

GEM (Gene Editing of the Microbiome) platform featuring Eligobiotics®: non-replicative DNA vectors for in vivo delivery of therapeutic payloads to target bacteria. Three modalities: SSAM (Sequence-Specific Anti-Microbials) for precision killing, GEM (Genome Editing) for in-situ base editing, and FAME (Function Addition) for adding therapeutic gene functions.

Funding History

1
Total raised:$30M
Series B$30M

Opportunities

The platform addresses the vast, unmet need for precision therapies in the microbiome space, particularly in combating antimicrobial resistance with narrow-spectrum agents.
Its modularity allows for expansion into multiple chronic disease areas with high market potential, creating a pipeline-in-a-product opportunity.

Risk Factors

Major technical risks include the challenge of efficient and specific in vivo delivery to target bacteria within a complex microbiome.
As a first-in-class modality, the company faces an undefined regulatory pathway and must prove clinical efficacy where broad microbiome interventions have shown variability.

Competitive Landscape

Eligo is a first-mover in in vivo microbiome gene editing. Competition includes other microbiome-focused biotechs using live biotherapeutic products (LBPs), phages, or small molecules, but few are pursuing precise genetic modification. Large pharma has shown interest in the microbiome but lacks comparable platform technology, positioning Eligo as a potential partner or acquisition target.

More companies in CRISPR / Gene Editing →More companies in France →